Interní Med. 2009; 11(4): 175-177
New antiplatelet drugs in cardiovascular disease treatment
- II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha
Antiplatelet therapy is the mainstay of both prevention and treatment of cardiovascular disease. However, the methods available have
numerous disadvantages, primarily including high rate of resistance or poor response to treatment. New antiplatelet drugs have superior
properties and lack a number of therapeutic limitations. The paper summarizes the effects of new reversible (ticagrelor and cangrelor)
as well as irreversible (prasugrel) platelet ADP receptor blockers, new platelet PAR-1 thrombin receptor inhibitors (SCH-530348) and new
options of blockade of thromboxane A2 synthesis (triflusal) or its receptor blockers (terutroban). As is evident, antithrombotic agents
with improved antiplatelet activity and more favourable pharmacokinetic properties can be expected.
Keywords: ADP receptor inhibitors, prasugrel, ticagrelor, cangrelor, PAR-1 thrombin receptor inhibitors, SCH-530348, terutroban.
Published: June 1, 2009 Show citation
References
- Mega JL, et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2008 Dec 22 (v tisku).
Go to original source... - Simon T, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med. 2008 Dec 22 (v tisku).
- Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 15, 357 (20): 2001-2015. Go to original source...
Go to PubMed... - Cannon CD, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007; 6, 50 (19): 1844-1851. Go to original source... Go to PubMed...
- O'Donnell MJ, et al. Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke. Stroke. 2008; 39 (5): 1638-1646. Go to original source... Go to PubMed...
- Angiolillo DJ, et al. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J. 2008; 156 (2 Suppl): S23-28. Go to original source... Go to PubMed...
- Chintala M, et al. Basic and translational research on proteinase-activated receptors: antagonism of the proteinaseactivated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci. 2008; 108 (4): 433-438. Go to original source... Go to PubMed...
- Koo MH, Nawarskas JJ, Frishman WH. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. Cardiol Rev. 2008; 16 (6): 314-318. Go to original source... Go to PubMed...
- Zeidner JF, Frishman WH, Lerner RG. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Cardiol Rev. 2008; 16 (5): 250-259. Go to original source... Go to PubMed...
- Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J. 2008; 156 (2 Suppl): S3-9. Go to original source... Go to PubMed...